Neuren - Latest News [Page 1]

NZ Biotech Phase 3 Drug Voted Top 10 By Experts

Monday, 21 July 2008, 4:48 pm | Neuren

SYDNEY Australia 21 July 2008: Neuren Pharmaceuticals (ASX: NEU) announced today that Glypromate® and NNZ-2566 for neuroprotection in cardiopulmonary bypass and traumatic brain injury (TBI) have been selected as one of the Top 10 most promising ... More >>

Neuren announces reorganisation

Monday, 12 November 2007, 5:40 pm | Neuren

Key points Neuren Pharmaceuticals CEO, David Clarke, to step down Dr Parmjot Bains named CEO for Australia/New Zealand business – based in Sydney Larry Glass named as CEO/President of US operations – based in Washington DC More >>

Neuren reports successful safety trial results

Wednesday, 7 November 2007, 12:42 am | Neuren

Neuren reports successful NNZ-2566 Phase 1b safety trial results Key points ·         Neuren successfully completes all cohorts of the Phase 1b study for NNZ-2566 to enable mild-moderate and severe Traumatic Brain Injury (TBI) trials to proceed More >>

TBI Phase 1b safety trial NNZ-2566 complete

Thursday, 20 September 2007, 12:51 am | Neuren

First two cohorts to support moderate TBI trial complete * Phase 2 TBI trial planning on track More >>

Neuren launches NZ arm of Global Phase 3 Trial

Saturday, 8 September 2007, 1:09 pm | Neuren

Friday 7 September 2007: The New Zealand biotech sector has moved into a new stage of development with the recruitment of New Zealand patients into a Phase 3 trial of a locally developed drug by Neuren Pharmaceuticals Limited (ASX: NEU). More >>

First Patient Enters Phase 3 Glypromate Trial

Thursday, 31 May 2007, 12:57 am | Neuren

Neuren Pharmaceuticals Ltd (ASX:NEU) today announced that the first patient has entered the Phase 3 clinical trial of its lead compound, Glypromate®, to reduce cognitive impairment in patients following cardiac surgery. The first patient was dosed at ... More >>

Clinical Trials Update

Thursday, 10 May 2007, 12:21 am | Neuren

U.S. sites for Glypromate® Phase 3 trial to be initiated this month * All sites selected and all drug manufacture completed for Phase 3 trial * All management and logistical resources in place for the Phase 3 trial * Phase 3 trial estimated to ... More >>

Neuren scientist NZ's first Laureate award

Monday, 26 February 2007, 12:22 am | Neuren

Neuren Pharmaceuticals (ASX: NEU) today announced that Professor Margaret Brimble, head of medicinal chemistry at the Company and researcher at the University of Auckland, is the first New Zealander to receive a Laureate award for scientific excellence ... More >>

US FDA approves Phase 3 IND for Glypromate

Wednesday, 31 January 2007, 11:58 am | Neuren

Neuren to initiate Phase 3 trial following the US FDA’s approval of the IND - Currently no treatments available to prevent cognitive impairment caused by cardiac bypass - Phase 3 trial conducted under US FDA authorisation moves Glypromate® towards a ... More >>

Drug candidate effective at reversing memory loss

Monday, 16 October 2006, 2:19 pm | Neuren

Neuren’s oral drug candidate NNZ-2591 has successfully reversed experimental memory loss, a common outcome associated with dementia and with many Parkinson’s disease patients More >>

New compound targeted for treatment of Parkinson's

Wednesday, 2 August 2006, 12:20 am | Neuren

Neuren Pharmaceuticals (ASX: NEU) announces a new lead candidate, NNZ-2591, from its diketopiperazine (DKP) family, which has shown efficacy in a preclinical model of Parkinson’s disease (PD) and in other animal models of brain injury. This is ... More >>

Neuren appoints Chief Operating Officer

Tuesday, 18 July 2006, 12:44 am | Neuren

Neuren Pharmaceuticals (ASX: NEU) announced today the appointment of Dr Parmjot Bains to the position of Chief Operating Officer. Dr Bains will be responsible for the operation of the clinical trial programs, ensuring overall responsibility for the ... More >>

Neuren granted US patent for NNZ-2566

Thursday, 11 May 2006, 3:54 pm | Neuren

Neuren Pharmaceuticals (ASX: NEU) is pleased to announce that its patent application entitled “GPE Analogs and Peptidomimetics” (PCT/US02/16361) has been issued in the United States (US Patent No: 7,041,314) on 9 May 2006. The patent describes Neuren’s ... More >>